Compare SENEA & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SENEA | ORGO |
|---|---|---|
| Founded | 1949 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 710.1M | 732.3M |
| IPO Year | N/A | N/A |
| Metric | SENEA | ORGO |
|---|---|---|
| Price | $110.36 | $4.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 72.7K | ★ 1.5M |
| Earning Date | 02-05-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.79 | N/A |
| EPS | ★ 8.61 | N/A |
| Revenue | ★ $1,606,175,000.00 | $465,218,000.00 |
| Revenue This Year | N/A | $8.14 |
| Revenue Next Year | N/A | $6.33 |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | ★ 8.33 | 2.24 |
| 52 Week Low | $70.58 | $2.61 |
| 52 Week High | $129.03 | $7.08 |
| Indicator | SENEA | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 45.20 | 33.71 |
| Support Level | $105.05 | $5.04 |
| Resistance Level | $111.47 | $5.35 |
| Average True Range (ATR) | 2.67 | 0.31 |
| MACD | 0.03 | -0.13 |
| Stochastic Oscillator | 61.04 | 3.00 |
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.